AI revolution in lung disease care: Brainomix and Boehringer Ingelheim forge game-changing partnership
Brainomix, a leader in artificial intelligence (AI) imaging solutions, has announced a partnership with the German pharmaceutical giant Boehringer Ingelheim. This collaboration aims to enhance ... Read More
Boehringer Ingelheim’s SENVELGO gets EU marketing authorization for feline diabetes treatment
The European Commission has granted marketing authorization to Boehringer Ingelheim for SENVELGO (active ingredient: velagliflozin), a groundbreaking development in the treatment of feline diabetes across ... Read More
Boehringer Ingelheim expands oncology portfolio with T3 Pharma acquisition
Boehringer Ingelheim announced its acquisition of T3 Pharmaceuticals AG (“T3 Pharma”), a Swiss biotech company specializing in immuno-oncology, for up to 450 million CHF. T3 ... Read More
Boehringer Ingelheim’s BI 690517 shows up to 39.5% albuminuria reduction in Phase II trial
Boehringer Ingelheim has revealed promising results from its 14-week Phase II trial for BI 690517, a novel selective aldosterone synthase inhibitor. The data highlights a ... Read More
Jardiance receives FDA approval to tackle kidney disease and cardiovascular risks
The U.S. Food and Drug Administration (FDA) has granted approval for Jardiance (empagliflozin) 10 mg tablets, a significant development announced jointly by Boehringer Ingelheim and ... Read More
Lupin, Mark Cuban’s Cost Plus Drugs and COPD Foundation boost COPD treatment access
In a significant healthcare development, global pharmaceutical giant Lupin Limited (Lupin) has entered into a groundbreaking collaboration with Mark Cuban Cost Plus Drug Company (Cost ... Read More
Lupin acquires diabetes brands ONDERO and ONDERO MET from Boehringer Ingelheim
In a strategic move to fortify its position in the pharmaceutical domain, global major Lupin Limited proclaimed its acquisition of coveted diabetes brands ONDERO and ... Read More
Survodutide shows promising results in Phase 2 study for weight loss in obese people
Boehringer Ingelheim and Zealand Pharma have announced further data showcasing the superior efficacy of survodutide (BI 456906) compared to placebo in individuals with overweight or ... Read More
Lupin clinches FDA approval for generic Spiriva HandiHaler
Indian pharma titan Lupin has announced receiving approval from the US Food and Drug Administration (FDA) for its Abbreviated New Drug Application for Tiotropium Bromide ... Read More
Glenmark Pharmaceuticals gets FDA approval for Nintedanib Capsules
Glenmark Pharmaceuticals Ltd said that it has secured tentative approval from the US Food and Drug Administration (FDA) for Nintedanib Capsules, 100mg, and 150mg. Nintedanib ... Read More